The molecular structure of bosutinib

Bosutinib (Bosutinib) is a kinase inhibitor. The chemical name of bosutinib monohydrate is 3-quinolinecarbonylnitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-hydrate (1:1). Its chemical formula is C26H29Cl2N5O3·H2O (monohydrate); its molecular weight is 548.46 (monohydrate), which is equivalent to 530.46 (anhydrate).

A trial called BFORE demonstrated the efficacy of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML) and reported adverse events similar to those previously seen in patients receiving second-line or subsequent treatment with bosutinib. When considering bosutinib as an option, or when switching from another TKI, questions about adverse events inevitably need to be considered. Lower bosutinib doses and appropriate adverse event management may allow patients to remain on treatment for longer periods of time, resulting in clinical benefit.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of the Turkish version may be more than RMB 2,000 per box of 500mg*28, and the price of the European version may be more than RMB 30,000 (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.